Biophytis SA (FR:ALBPS) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Biophytis SA, a biotech firm, has signed an exclusive deal potentially worth €108M with Blanver for the rights to market their lead drug candidate BIO101 in Latin America. This partnership could also yield Biophytis double-digit royalties on BIO101’s future sales in the region. The collaboration includes joint clinical development and manufacturing for the treatment of diseases such as obesity and Duchenne Muscular Dystrophy.
For further insights into FR:ALBPS stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue